FY2025 EPS Estimates for Vericel Lowered by Leerink Partnrs

Key Points

• Leerink Partners has decreased their FY2025 earnings per share estimate for Vericel Corporation from $0.33 to $0.23, while the consensus estimate stands at $0.14.
• Vericel reported a quarterly earnings result of ($0.01) EPS, exceeding analysts' estimates and showing a 20.1% increase in revenue year-over-year.
• Vericel stock is currently rated as a "Moderate Buy" with an average price target of $59.86 from analysts, despite some brokerage downgrades in recent months.

Vericel Corporation (NASDAQ:VCEL - Free Report) - Analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for Vericel in a report released on Thursday, July 31st. Leerink Partnrs analyst M. Kratky now expects that the biotechnology company will post earnings per share of $0.23 for the year, down from their previous estimate of $0.33. The consensus estimate for Vericel's current full-year earnings is $0.14 per share. Leerink Partnrs also issued estimates for Vericel's FY2026 earnings at $0.67 EPS, FY2027 earnings at $1.20 EPS and FY2028 earnings at $1.86 EPS.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.03. Vericel had a return on equity of 2.47% and a net margin of 2.85%. The firm had revenue of $63.24 million for the quarter, compared to analysts' expectations of $64.61 million. During the same period in the previous year, the firm earned ($0.10) EPS. The business's quarterly revenue was up 20.1% on a year-over-year basis.

A number of other research analysts have also recently commented on VCEL. Stephens reissued an "overweight" rating and issued a $67.00 price target on shares of Vericel in a report on Monday, June 16th. Wall Street Zen downgraded Vericel from a "hold" rating to a "sell" rating in a research report on Monday, May 12th. Truist Financial cut their price objective on Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Finally, Canaccord Genuity Group cut their price objective on Vericel from $61.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, Vericel presently has a consensus rating of "Moderate Buy" and a consensus price target of $59.86.

Vericel Price Performance

Shares of VCEL stock traded down $0.76 during trading hours on Monday, reaching $36.82. 489,419 shares of the company traded hands, compared to its average volume of 658,810. Vericel has a 12-month low of $33.09 and a 12-month high of $63.00. The company has a market cap of $1.86 billion, a P/E ratio of 306.86 and a beta of 1.27. The firm has a 50-day moving average price of $40.76 and a 200 day moving average price of $45.25.

Hedge Funds Weigh In On Vericel

Hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its stake in shares of Vericel by 2.7% during the 1st quarter. Principal Financial Group Inc. now owns 270,154 shares of the biotechnology company's stock worth $12,054,000 after purchasing an additional 7,222 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Vericel by 15.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 204,510 shares of the biotechnology company's stock worth $9,125,000 after purchasing an additional 27,526 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Vericel by 34.8% during the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company's stock worth $129,000 after purchasing an additional 748 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Vericel by 26.5% during the 4th quarter. JPMorgan Chase & Co. now owns 571,194 shares of the biotechnology company's stock worth $31,364,000 after purchasing an additional 119,574 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Vericel by 11.8% during the 4th quarter. Wells Fargo & Company MN now owns 69,975 shares of the biotechnology company's stock worth $3,842,000 after purchasing an additional 7,363 shares during the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.